Oncolytics Biotech Inc.
ONCYHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The $65.9M market capitalization puts ONCY squarely in micro-cap range for its industry. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Market Cap
$65.9M
Beta
1.16
P/E (TTM)
—
P/E (Fwd)
-2.52
EPS (TTM)
$-0.35
EPS (Fwd)
$-0.20
ROE
—
ROA
-211.2%
Cash
$4.1M
Total Debt
$448,000
Free CF
-$12.0M
52W Change
-58.3%
Annual Financials
Cash vs Debt
Where ONCY stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ONCY finished 40.48% below its 150-day moving average ($0.84) and 43.82% below its 200-day moving average ($0.89). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ONCY overbought or oversold?
At the October 20, 2026 close, ONCY's RSI(14) was 27.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Oncolytics Biotech Inc. holds $4.1M in cash against $448K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$12.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
With cash comfortably exceeding debt, ONCY has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ONCY's risk profile alongside its fundamentals and technical indicators provides a more complete picture.